PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Attana AB

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Tecan Group and Attana AB Sign Distribution Agreement in North America - The Tecan Group (SIX Swiss Exchange: TECN) and Attana AB today announced that they have signed an exclusive distributor agreement under which Tecan will distribute Attana's biosensor
Tecan Group and Attana AB Sign Distribution Agreement in North America

 

NewswireToday - /newswire/ - Stockholm, Sweden, 2011/01/12 - The Tecan Group (SIX Swiss Exchange: TECN) and Attana AB today announced that they have signed an exclusive distributor agreement under which Tecan will distribute Attana's biosensor.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The Tecan Group and Attana AB today announced that they have signed an exclusive distributor agreement under which Tecan will distribute Attana's biosensor instruments and assay technology in North America. The agreement covers the Attana 100, 200 and Cell 200 instruments along with biosensors and accompanying assay reagents as well as service and support. The distribution agreement leverages Tecan’s sales, service and applications capabilities in North America with Attana’s biosensor technology that allows in-depth analyses of molecular interactions in a wide variety of research applications.

Thomas Bachmann, CEO of Tecan, said: “We are delighted that we have been able to partner with Attana on such an exciting label free biosensor detection technology. This agreement allows us to offer our North American customers another dimension of information in their scientific disciplines. It is part of our strategy to leverage our own sales organization for innovative third party products that complement the broad product portfolio of our Life Sciences Business.”

“We are pleased to have reached an agreement with such a well established and innovative company”, says Teodor Aastrup, CEO and founder of Attana. “We are confident that this collaboration will be beneficiary to the biopharmaceutical and academic society as a more comprehensive product portfolio will be offered to both Tecan’s and Attana’s customers. Tecan has a strong position on the North American market and will reach even further with Attana’s biosensor technologies.”

Tecan and Attana will be officially launching their collaboration today at the CHI-PepTalk Conference in San Diego, USA.

About Tecan
Tecan (tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).

About Attana AB
Founded in 2002, based in Stockholm, Sweden, Attana AB (attana.com) develops biosensors for the pharmaceutical, diagnostic and academic society worldwide. With a strong focus on characterizing molecular interactions exactly as they occur in the human body, Attana is committed to increasing the success during clinical trials by providing the life science community with biologically relevant information. Attana’s biosensors can be used to determine specificity, kinetics and affinity, amongst other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.

For further information:

Tecan Group
Martin Braendle, Head of Corporate Communications & Investor Relations
T: +41 (0) 44 922 84 30 / F: +41 (0) 44 922 88 89 - E: investor[.]tecan.com.

Attana AB
Gabriela Suhoschi, Marketing Manager
T: +46 (0) 8 674 57 12 / E: gabriela.suhoschi[.]attana.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Attana AB

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Tecan Group and Attana AB Sign Distribution Agreement in North America

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Li Huimin - Attana.com 
+46 (0)8 410 200 00 gabriela.suhoschi[.]attana.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Attana AB securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Attana AB / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)